ArrowMark Colorado Holdings LLC Has $7.52 Million Stake in C4 Therapeutics, Inc. (NASDAQ:CCCC)

ArrowMark Colorado Holdings LLC boosted its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCCFree Report) by 6.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,319,484 shares of the company’s stock after purchasing an additional 75,126 shares during the quarter. ArrowMark Colorado Holdings LLC’s holdings in C4 Therapeutics were worth $7,521,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Wasatch Advisors LP lifted its stake in shares of C4 Therapeutics by 17.1% in the third quarter. Wasatch Advisors LP now owns 5,677,368 shares of the company’s stock valued at $32,361,000 after buying an additional 830,218 shares in the last quarter. MetLife Investment Management LLC lifted its position in C4 Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 35,455 shares of the company’s stock valued at $202,000 after acquiring an additional 19,978 shares in the last quarter. Cynosure Group LLC acquired a new position in C4 Therapeutics during the 3rd quarter valued at about $57,000. FMR LLC increased its holdings in C4 Therapeutics by 687.0% during the 3rd quarter. FMR LLC now owns 185,941 shares of the company’s stock worth $1,060,000 after purchasing an additional 162,314 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of C4 Therapeutics by 81.8% in the third quarter. The Manufacturers Life Insurance Company now owns 41,664 shares of the company’s stock worth $237,000 after purchasing an additional 18,746 shares during the last quarter. Institutional investors and hedge funds own 78.81% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Stephens assumed coverage on C4 Therapeutics in a research report on Monday, November 18th. They set an “equal weight” rating and a $4.00 target price on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $20.00 target price on shares of C4 Therapeutics in a research note on Tuesday, August 6th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, C4 Therapeutics presently has an average rating of “Hold” and an average target price of $10.00.

Get Our Latest Report on CCCC

C4 Therapeutics Stock Down 5.5 %

C4 Therapeutics stock opened at $4.30 on Tuesday. The company has a market capitalization of $303.53 million, a P/E ratio of -2.54 and a beta of 3.04. The firm has a 50 day moving average price of $5.48 and a 200-day moving average price of $5.57. C4 Therapeutics, Inc. has a twelve month low of $1.06 and a twelve month high of $11.88.

C4 Therapeutics (NASDAQ:CCCCGet Free Report) last released its earnings results on Thursday, October 31st. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. The business had revenue of $15.36 million during the quarter, compared to the consensus estimate of $5.95 million. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. Equities analysts expect that C4 Therapeutics, Inc. will post -1.48 EPS for the current fiscal year.

C4 Therapeutics Profile

(Free Report)

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.

Featured Articles

Want to see what other hedge funds are holding CCCC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C4 Therapeutics, Inc. (NASDAQ:CCCCFree Report).

Institutional Ownership by Quarter for C4 Therapeutics (NASDAQ:CCCC)

Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.